NCT06989892Recruiting
Comparing Super High-flux and High-flux Dialyzer Performance Among Hemodialysis Patient With Sepsis : a Randomized Control Trial
Source: ClinicalTrials.gov · Last updated 25 May 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Comparing the efficacy of superhigh-flux dialyzer with high-flux dialyzer in ESKD patient who have sepsis to improve mortality and sepsis outcome, an open label randomized control trial.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 202 (estimated)
- First submitted
- 24 Jul 2024
- Start date
- 25 Jul 2024
- Primary completion date
- 1 Jul 2026
- Lead sponsor
- Navamindradhiraj University
- Diseases
- Chronic kidney disease
- NCT number
- NCT06989892
What you commit to
- Study type: Interventional
- Planned participants: 202
- From 25 Jul 2024 to the primary completion date, 1 Jul 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who needed dialysis with continuous kidney replacement therapy, vulnerable patient, include pregnant woman, patient who expected to pass away within the 24 hours.
Other illness
- Patients who have the history of allergic dialyzer reaction to dialyzer which used in this trial.
Who the study is looking for
- ESKD patients who have sepsis condition with high interleukin-6 (IL-6 \> 50 pg/ml)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Navamindhradhiraj university Coordinator of this site? Confirm its status | Dusit | Thailand | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.